Table 2. Assessment	of Quality of Included Cross-Se	ectional Studie	es Using the Modif	ied Newcastle-Ottawa	a Scale ^a			
					Comparability (out of 2) The subjects in different outcome			
	Selection (out of 5) ^b Ascertainment of				groups are comparable, based on the study design or analysis. Confounding	Outco Assessment	ome (out of 2)	Total score
Author (year) Palagini et al ¹⁸ (2022)	Representativeness of sample	Sample size	exposure **	Nonrespondents	factors are controlled **	of outcome	Statistical test	(out of 9)
	(Somewhat representative of the average in the target population/non-random sampling)	(Justified and satisfactory)	(Validated measurement tool)	(Comparability between responders and nonresponders not established)	(Controlled for current pharmacologic treatments, suicidal attempts, and illness duration)		(Clearly described and appropriate)	
Palagini et al ¹⁹ (2022)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(Comparability between responders and nonresponders not established)	** (Controlled for current pharmacologic treatments and illness duration)	* (Self-report)	* (Clearly described and appropriate)	8
Echezarraga et al ²⁰ (2022)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for age, gender, marital status, education level, and employment status)	* (Self-report)	* (Clearly described and appropriate)	8
Dou et al ²¹ (2022)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for age and gender)	* (Self-report)	* (Clearly described and appropriate)	7
Fernández-Rocha et al ²² (2021)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	(Not controlled for)	* (Self-report)	* (Clearly described and appropriate)	6
Aslan and Baldwin ²³ (2021)	(No description of sampling strategy)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for duration of illness and illness age of onset)	* (Self-report)	* (Clearly described and appropriate)	6
Citak and Erten ²⁴ (2021)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the characteristics of the nonresponders)	(Not controlled for)	* (Self-report)	* (Clearly described and appropriate)	6
Nunes and da Rocha ²⁵ (2021)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the characteristics of the nonresponders)	** (Controlled for several clinical variables)	* (Self-report)	* (Clearly described and appropriate)	7
Post et al ⁶ (2021)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the characteristics of the nonresponders)	(Not controlled for)	* (Self-report)	* (Clearly described and appropriate)	5
Verdolini et al ²⁶ (2021)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for variables related to COVID-19 and subgroup)	* (Self-report)	* (Clearly described and appropriate)	8
Masi et al ²⁷ (2020)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for mean age and frequency of BP types)	* (Self-report)	and appropriate)	7
Pardeller et al ²⁸ (2020)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for age, sex, education)	* (Self-report)	* (Clearly described and appropriate)	7
Şenormancı et al ²⁹ (2020)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	(Not controlled for)	* (Self-report)	* (Clearly described and appropriate)	5
Vieira et al ³⁰ (2020)	* (Truly representative of the average in the target population/random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of characteristics of the nonresponders)	** (Controlled for sex, skin color, socioeconomic status, suicide risk)	* (Self-report)	* (Clearly described and appropriate)	8
Uygun et al ³¹ (2020)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for age, gender, age at onset)	* (Self-report)	* (Clearly described and appropriate)	7
Sánchez et al ³² (2018)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	(Not controlled for)	* (Self-report)	* (Clearly described and appropriate)	5
Sivri et al ³³ (2019)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the characteristics of the nonresponders)	* (Controlled for effect of psychopathology)	* (Self-report)	* (Clearly described and appropriate)	6
Bozikas et al ³⁴ (2018)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(Comparability between responders and nonresponders not established)	** (Controlled for years of education and duration of illness)	* (Self-report)	* (Clearly described and appropriate)	8
Chung et al ³⁵ (2018)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for several clinical and demographic variables)	* (Self-report)	* (Clearly described and appropriate)	7
Deng et al ³⁶ (2018)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for years of education, gender, marital status, employment)	* (Self-report)	and appropriate)	7
Mizuno et al ³⁷ (2018)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	* (Controlled for age)	* (Self-report)	* (Clearly described and appropriate)	7
Post et al ³⁸ (2018)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for age, sex, education)	* (Self-report)	* (Clearly described and appropriate)	8
Lee et al ³⁹ (2017)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for several clinical and demographic variables)	* (Self-report)	* (Clearly described and appropriate)	7
Hofer et al ⁴⁰ (2017)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	* (Controlled for education)	* (Self-report)	* (Clearly described and appropriate)	6
Mizuno et al ¹² (2016)	* (Somewhat representative of the average in the target population/non-random sampling)	* (Justified and satisfactory)	** (Validated measurement tool)	(No description of the characteristics of the nonresponders)	** (Controlled for age, marital situation, working situation)	* (Self-report)	* (Clearly described and appropriate)	8
Choi et al ⁴¹ (2015)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	** (Controlled for occupation, length of education)	* (Self-report)	* (Clearly described and appropriate)	7
Kesebir et al ⁴² (2015)	* (Somewhat representative of the average in the target population/non-random sampling)	(Not justified)	** (Validated measurement tool)	(No description of the response rate or the characteristics of the nonresponders)	(Not controlled for)	* (Self-report)	* (Clearly described and appropriate)	5
^a Asterisks indicate the nur	mber of stars earned in each area on th	e Newcastle-Otta	wa Scale.					